Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan
ConclusionsAchievement of age-defined glycaemic targets with iGlarLixi treatment for 6 months was significantly affected by increased age and body weight loss, regardless of prior insulin exposure.Trial RegistrationUMIN-CTR Trials Registry, UMIN000044126; registered 10 May 2021.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Diabetes | Endocrinology | Gastroenterology | Insulin | Japan Health | Lantus | Study | Weight Loss